RxDoctor Payments Data

Tabitha Green, APRN

Family · Central City, KYNPI 1578817110

Payments from drug & device makers

$309in general payments, 2019–2025

Across 19 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$72
  • Novartis$47
  • AbbVie$46
  • Lilly USA, LLC$27
  • Pfizer$25
  • AstraZeneca$19
  • plus $74 from 6 others

What the payments were for

  • Food & beverage$309100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk4$72
Novartis3$47
AbbVie2$46
Lilly USA, LLC2$27
Pfizer1$25
AstraZeneca1$19
Merck1$16
GSK1$15
Amgen1$13
Bayer1$13
Abbott1$12
Genentech USA, Inc.1$3

How this compares

$309 in reported general payments places this provider in the 40th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$672
Medicare patients
28
Services billed
40

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin38$29,795
OzempicSemaglutide31$29,184
TrulicityDulaglutide14$16,426
JanuviaSitagliptin Phosphate11$11,449
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,612
Emgality PenGalcanezumab-Gnlm11$7,789
Aripiprazole22$7,125
VascepaIcosapent Ethyl12$4,183
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,238
Atorvastatin Calcium151$1,156
Pantoprazole Sodium104$1,019
Albuterol Sulfate HfaAlbuterol Sulfate38$1,010
Oxybutynin Chloride ErOxybutynin Chloride17$998
Ventolin HfaAlbuterol Sulfate14$892
Potassium Chloride37$628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$72$29,18431 claims
Lilly USA, LLCTrulicity$27$16,42614 claims
MerckJanuvia$16$11,44911 claims
GSKTrelegy Ellipta$15$9,61215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 4,374 family providers in Kentucky.

Other family in Central City

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →